Physician profile
David A Diffine
NPI 1679576631
$1,524.03
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $201 · 2020: $108 · 2021: $269 · 2022: $256 · 2023: $124 · 2024: $565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $689.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $689.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $685.20 | 2021-2024 | Vraylar |
| Glaxosmithkline, LLC. | $229.99 | 2020-2023 | Trelegy Ellipta |
| Allergan, INC. | $128.80 | 2019 | |
| Lilly USA, LLC | $106.29 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $100.80 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $54.48 | 2024 | Farxiga, Breztri |
| Axsome Therapeutics, INC. | $45.62 | 2024 | Auvelity |
| Axonics, INC. | $36.44 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $32.94 | 2022 | |
| Pfizer INC. | $24.97 | 2021 | |
| Biodelivery Sciences International, INC. | $23.84 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.27 | 2022 | |
| Eisai INC. | $16.29 | 2021 | |
| Supernus Pharmaceuticals, INC. | $16.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Diffine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.